Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KB707 · 2 trials · 9 indications
Percentage of subjects with treatment-related AEs as assessed by NCI-CTCAE v5
Percentage of subjects with adverse events (AEs)
Percentage of subjects with serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Cohorts 1 through 4 | EXPERIMENTAL | Dose escalation and expansion cohorts: KB707 monotherapy in subjects with solid tumor malignancies affecting the lungs. |
| Cohort 5 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with Keytruda in approximately 60 subjects with NSCLC. |
| Cohort 6 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with Keytruda and chemotherapy in approximately 60 subjects with NSCLC. |
| Experimental: Cohort 7 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with docetaxel in approximately 50 subjects with NSCLC. |
| Name | Type | Description |
|---|---|---|
| KB707 | BIOLOGICAL | Genetically modified herpes simplex type 1 virus |
| Pembrolizumab (KEYTRUDA®) | DRUG | PD-1 immune checkpoint inhibitor |
| Chemotherapy | DRUG | SOC chemotherapy |
| Docetaxel | DRUG | SOC chemotherapy |
| Opdualag | DRUG | Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors) |
| KEYTRUDA ®( Pembrolizumab) | DRUG | Immunotherapy (PD-1 immune checkpoint inhibitor) |
Key Inclusion Criteria: * Age 18 years or older at the time of informed consent * Life expectancy \>12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have at least one measurable lung lesion per RECIST v1.1 at Screening * Cohorts 1 through 4 only: Histologically co...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
KB707 is an investigational monoclonal antibody being developed for the treatment of cancer, including non-small cell lung cancer and other advanced solid tumors. It is currently in Phase 1 clinical trials for these indications.
KB707 targets IL-2, a cytokine involved in immune response. By targeting IL-2, KB707 is designed to modulate immune activity in the tumor microenvironment, potentially enhancing the body's ability to fight cancer cells.
KB707 is being developed by Krystal Biotech, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KRYS.
KB707 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing trials are recruiting participants to evaluate its safety and efficacy.
KB707 is being studied in two Phase 1 trials: NCT05970497, which assesses KB707 for locally advanced or metastatic solid tumors including melanoma, and NCT06228326, which focuses on advanced solid tumors affecting the lungs, including non-small cell lung cancer. Both trials are recruiting in the United States.
No alternative names for KB707 have been disclosed. It is a distinct investigational agent developed by Krystal Biotech.